Common Data Elements Analysis of Mechanical Thrombectomy Clinical Trials for Acute Ischemic Stroke with Large Core Infarct. Clinical neuroradiology Jabal, M. S., Ibrahim, M. K., Thurnham, J., Kallmes, K. M., Kobeissi, H., Ghozy, S., Hardy, N., Tarchand, R., Bilgin, C., Heit, J. J., Brinjikji, W., Kallmes, D. F. 2022

Abstract

BACKGROUND: Clinical trials addressing large core acute ischemic stroke (AIS) are ongoing across multiple international groups. Future development of clinical guidelines depends on meta-analyses of these trials calling for adegree of homogeneity of elements across the studies. This common data element study aims to provide an overview of key features of pertinent large core infarct trials.METHODS: PubMed and ClinicalTrials.gov databases were screened for published and ongoing clinical trials assessing mechanical thrombectomy in patients with AIS with large core infarct. Nested Knowledge AutoLit living review platform was utilized to categorize primary and secondary outcomes as well as inclusion and exclusion criteria for patient selection in the trials.RESULTS: The most reported data element was ASPECTS score but with varied definitions of what constitutes large core. Non-utility-weighted modified Rankin score (mRS) was reported in 6/7studies as the primary outcome, while the utility-weighted mRS was the outcome of interest in the TESLA trial, all of them at the 3 months mark, with only LASTE looking for mRS shift at the 6 months mark. Secondary outcomes had more variations. Mortality is reported separately only in 4/7trials, all at the 3-month mark. Additionally, the TENSION trial reported the frequency of serious adverse events, including mortality, at the 1-week and 12-month mark.DISCUSSION: Overall, in large core trials there is alarge degree of heterogeneity in the collected data elements. Differences in definition and timepoints render reaching aunified standard difficult, which hinders high quality meta-analyses and cohesive evidence-driven synthesis.

View details for DOI 10.1007/s00062-022-01239-x

View details for PubMedID 36520186